Theravance Biopharma (NASDAQ:TBPH) Cut to Market Perform at Oppenheimer

Oppenheimer downgraded shares of Theravance Biopharma (NASDAQ:TBPH) from an outperform rating to a market perform rating in a research note published on Thursday morning, MarketBeat Ratings reports.

A number of other equities analysts have also recently issued reports on TBPH. HC Wainwright raised their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. BTIG Research cut their price target on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. B. Riley Financial reaffirmed a “neutral” rating and set a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday. Finally, Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Theravance Biopharma Trading Down 0.1%

Theravance Biopharma stock opened at $13.57 on Thursday. The company has a market cap of $687.59 million, a PE ratio of 23.81 and a beta of 0.17. Theravance Biopharma has a 1 year low of $7.90 and a 1 year high of $21.03. The company’s 50-day moving average is $18.95 and its two-hundred day moving average is $16.85.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its stake in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its stake in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 4,662 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma News Roundup

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: HC Wainwright sharply raised FY‑2026 and quarterly EPS forecasts and keeps a Buy rating and $27 target, signaling materially improved earnings expectations that could support a rebound. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Zacks highlights the stock as deeply oversold after a ~30% four‑week decline and notes analyst upward estimate revisions, arguing the pullback may be a buying opportunity for a technical reversal. Zacks: Buy the dip
• Neutral Sentiment: Market context: TBPH is trading with above‑average volume, inside its 1‑year range ($7.90–$21.03) and below the 50‑day moving average — a mixed technical picture that increases sensitivity to news flow.
• Negative Sentiment: Theravance reported a late‑stage drug trial failure that prompted a sharp share decline and workforce reductions, a material fundamental negative that reduces near‑term upside. Share tumbles and jobs to go after Theravance failure
• Negative Sentiment: Management is reportedly considering a possible sale after the trial setback, which introduces strategic uncertainty and potential valuation pressure while options are explored. MSN: Possible sale after trial setback
• Negative Sentiment: Oppenheimer downgraded TBPH from Outperform to Market Perform, signaling reduced near‑term conviction from a major bank and likely contributing to selling pressure. Oppenheimer downgrades Theravance
• Negative Sentiment: BTIG issued a pessimistic forecast for the stock, adding to negative analyst sentiment and raising downside risk until clarity on the pipeline or strategic actions emerges. BTIG pessimistic forecast

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.